ATE510553T1 - Beta-2-glycoprotein 1 als angiogenesehemmer - Google Patents

Beta-2-glycoprotein 1 als angiogenesehemmer

Info

Publication number
ATE510553T1
ATE510553T1 AT03755330T AT03755330T ATE510553T1 AT E510553 T1 ATE510553 T1 AT E510553T1 AT 03755330 T AT03755330 T AT 03755330T AT 03755330 T AT03755330 T AT 03755330T AT E510553 T1 ATE510553 T1 AT E510553T1
Authority
AT
Austria
Prior art keywords
tissue
glycoprotein
beta
angiogenesis inhibitor
β2gp1
Prior art date
Application number
AT03755330T
Other languages
English (en)
Inventor
Alan Schroit
Krishnakumar Balasubramanian
Marya Mccarty
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE510553T1 publication Critical patent/ATE510553T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
AT03755330T 2002-05-17 2003-04-02 Beta-2-glycoprotein 1 als angiogenesehemmer ATE510553T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38121902P 2002-05-17 2002-05-17
PCT/US2003/010188 WO2003099833A2 (en) 2002-05-17 2003-04-02 Beta-2-glycoprotein 1 is an inhibitor of angiogenesis

Publications (1)

Publication Number Publication Date
ATE510553T1 true ATE510553T1 (de) 2011-06-15

Family

ID=29584304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03755330T ATE510553T1 (de) 2002-05-17 2003-04-02 Beta-2-glycoprotein 1 als angiogenesehemmer

Country Status (5)

Country Link
US (3) US7329642B2 (de)
EP (1) EP1515754B1 (de)
AT (1) ATE510553T1 (de)
AU (1) AU2003273176A1 (de)
WO (1) WO2003099833A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE510553T1 (de) * 2002-05-17 2011-06-15 Univ Texas Beta-2-glycoprotein 1 als angiogenesehemmer
ES2527870T5 (es) 2003-04-08 2022-10-14 Progenics Pharm Inc Formulaciones farmacéuticas que contienen metilnaltrexona
JP5047783B2 (ja) * 2004-05-13 2012-10-10 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク（セーエヌエールエス） ターゲット存在物をおとり存在物へ結合させるための装置、および該装置を使用する検出方法
US8956616B2 (en) * 2005-01-24 2015-02-17 Board Of Regents, The University Of Texas System Constructs binding to phosphatidylserine and their use in disease treatment
US20090048158A1 (en) * 2005-02-18 2009-02-19 Moreno Maria J Insulin-Like Growth Factor Binding Protein-4 Compounds and Methods for Inhibiting Angiogenesis and Tumor Growth in Mammalian Cells
WO2006096626A2 (en) 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
EP3263571B2 (de) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Kristallform von (r)-n-methylnaltrexonebromide und verwendungen davon
TWI466671B (zh) 2007-03-29 2015-01-01 Progenics Pharm Inc 末梢性類鴉片受體拮抗劑及其用途
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101143207B (zh) * 2007-08-28 2011-04-27 于德民 天然型、断裂型或第V结构域缺失突变型β2糖蛋白I在制备抑制血管新生药物中的应用
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
EP2278966B1 (de) 2008-03-21 2019-10-09 The University of Chicago Behandlung mit opioid-antagonisten und mtor-inhibitoren
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2012030949A2 (en) * 2010-09-01 2012-03-08 Kansas State University Research Foundation B2-glycoprotein i peptide inhibitors
WO2016036949A1 (en) * 2014-09-03 2016-03-10 The Regents Of The University Of California Methods to determine the distribution profiles of circulating rnas
CN105550461B (zh) * 2015-12-30 2018-10-02 哈尔滨理工大学 一种基于断端微动和血供的骨折愈合仿真系统
WO2017133018A1 (zh) * 2016-02-06 2017-08-10 法玛科技顾问股份有限公司 重组β2-糖蛋白胜肽及其于抗肿瘤的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US20060025329A1 (en) 1997-02-06 2006-02-02 Todd Hembrough Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
NZ508873A (en) 1998-07-13 2003-10-31 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
GB9815505D0 (en) 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
WO2000054801A1 (en) 1999-03-17 2000-09-21 Entremed, Inc. Compositions and methods of use of ldl-like receptor ligands for the treatment of cancer and angiogenic-based disease
US6743428B1 (en) 1999-09-15 2004-06-01 Mogam Biotechnology Research Institute Angiogenesis inhibitor
EP1355664A4 (de) 2001-01-04 2005-10-26 Vascular Biogenics Ltd "verfahren, bei denen plaque?assoziierte moleküle verwendet werden sowie zusammensetzungen, die diese enthalten; für die vorbeugung und behandlung von atheriosklerose"
ATE510553T1 (de) * 2002-05-17 2011-06-15 Univ Texas Beta-2-glycoprotein 1 als angiogenesehemmer

Also Published As

Publication number Publication date
WO2003099833A2 (en) 2003-12-04
WO2003099833A3 (en) 2004-08-26
US7642234B2 (en) 2010-01-05
US20030219406A1 (en) 2003-11-27
US7329642B2 (en) 2008-02-12
AU2003273176A1 (en) 2003-12-12
US20080131397A1 (en) 2008-06-05
AU2003273176A8 (en) 2003-12-12
EP1515754B1 (de) 2011-05-25
EP1515754A2 (de) 2005-03-23
US20100226887A1 (en) 2010-09-09
EP1515754A4 (de) 2007-06-20

Similar Documents

Publication Publication Date Title
ATE510553T1 (de) Beta-2-glycoprotein 1 als angiogenesehemmer
TW200621240A (en) Cancer treatments
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
CO5271702A1 (es) Compuesto anticanceroso y metodo de separacion de enantiomeros utiles para sintetizar dicho compuesto
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
ATE324444T1 (de) Tek-antagonisten
ATE541571T1 (de) Diarylhydantoin-verbindung
DK0768885T3 (da) Fremgangsmåde til inhibering af cancermetastase ved oral administration af oplöselig modificeret citruspectin
ATE408412T1 (de) Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
WO2004037235A3 (en) Method and composition for preventing and treating solid tumors
TW200800975A (en) New compounds 2
EA200400235A1 (ru) Комбинированная терапия для лечения рака
WO2005009434A3 (en) Compounds and methods for inducing apoptosis in cancer cells
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
DK1480627T3 (da) Fremgangsmåder til mindskelse af angiogenese
RS20070095A (en) Alkyliden-tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents
WO2001032210A3 (en) Compositions for treating atheroma and neoplastic tissue
WO2002080854A3 (en) Compositions and methods for the prevention and treatment of human prostate cancer
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
WO2020176461A3 (en) Methods and compositions for treating neuroendocrine prostate cancer
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
MX2007005501A (es) Asociacion tumoral de mieloide de lectina-1 asociada a dap12 y metodos.
MXPA02008014A (es) Composiciones inhibidoras de tumores de 1-nitroacridina.
DE60312988D1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties